BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ALXN2350 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ALXN2350\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07218887-11162@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20320127
DTEND;VALUE=DATE:20320128
SUMMARY:ALXN2350: Phase 1/2 readout est. (NCT07218887)
DESCRIPTION:ALXN2350\, phase 1/2\, Dilated Cardiomyopathy.\nStudy: ALXN2350
  in Adult Participants With BAG3-Associated Dilated Cardiomyopathy\nEstima
 ted primary completion: 27 January 2032. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/alxn2350#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07218887
URL:https://assetmemo.bio/drug/alxn2350#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
